Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial

恩帕吉菲 医学 利格列汀 安慰剂 2型糖尿病 二甲双胍 内科学 养生 糖尿病 临床终点 随机对照试验 胰岛素 内分泌学 病理 替代医学
作者
Lori M. Laffel,Thomas Danne,Georgeanna J. Klingensmith,William V. Tamborlane,Steven M. Willi,Philip Zeitler,Dietmar Neubacher,Jan Marquard,Т. П. Бардымова,Margarita Barrientos Perez,Kathleen E. Bethin,Petter Bjornstad,Ирина Аркадьевна Бондарь,Mimi Chen,Jin‐Ho Choi,Mark A. Clements,Javier Ricardo Colomar,Mark Daniels,Chaicharn Deerochanawong,Vivek S Desai
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:11 (3): 169-181 被引量:100
标识
DOI:10.1016/s2213-8587(22)00387-4
摘要

Summary

Background

The incidence of type 2 diabetes in young people is increasing, but treatments remain limited. We aimed to assess the efficacy and safety of an empagliflozin dosing regimen versus placebo and linagliptin versus placebo on glycaemic control in young people with type 2 diabetes.

Methods

In this double-blind, placebo-controlled trial done in 108 centres in 15 countries, participants with type 2 diabetes (aged 10–17 years; HbA1c 6·5–10·5% [48–91 mmol/mol]) who had been previously treated with metformin or insulin were randomly assigned (1:1:1) to oral empagliflozin 10 mg, oral linagliptin 5 mg, or placebo. Participants in the empagliflozin group who did not have HbA1c below 7·0% (<53 mmol/mol) by week 12 underwent a second double-blinded randomisation (1:1) at week 14, either remaining on 10 mg or increasing to 25 mg. Participants in the placebo group were randomly reassigned (1:1:1) in a double-blinded manner at week 26 to linagliptin 5 mg or one of the empagliflozin doses (10 mg or 25 mg). Investigators were masked throughout the trial and received assignments of blinded medication kits through interactive response technology for all participants at the initial randomisation and for the re-randomisations at weeks 14 and 26. The primary outcome was change from baseline in HbA1c at 26 weeks. For empagliflozin, results were based on a pooled analysis for all participants on empagliflozin. Safety was assessed until week 52. This trial is registered with ClinicalTrials.gov, NCT03429543.

Findings

Between April 26, 2018, and May 26, 2022, of 262 screened participants, 158 (60%) were randomly assigned to treatment (53 [34%] to placebo, 52 [33%] to empagliflozin 10 mg, and 53 [34%] to linagliptin). For the primary outcome, the adjusted mean HbA1c change from baseline at week 26 was –0·84% [–9·2 mmol/mol] in the empagliflozin pooled group versus placebo (95% CI –1·50 to –0·19 [–16·4 to −2·1]; p=0·012); the corresponding change from baseline for linagliptin versus placebo was –0·34% [–3·8 mmol/mol; 95% CI –0·99 to 0·30 [–10·8 to 3·3]; p=0·29). Adverse events occurred in 34 (64%) participants in the placebo group, 40 (77%) in the empagliflozin pooled group, and 37 (71%) in the linagliptin group, up to week 26. Of these, severe adverse events were reported in two (4%) participants in the placebo group, one (2%) in the empagliflozin pooled group, and one (2%) in the linagliptin group. Hypoglycaemia was the most frequently reported adverse event with higher rates for those on active drug treatment compared with placebo. No severe hypoglycaemia cases were reported.

Interpretation

Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.

Funding

The Boehringer Ingelheim and Eli Lilly and Company Alliance.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
火星上的煎蛋的应助被小SCI采纳,获得10
刚刚
dxftx发布了新的文献求助10
1秒前
秋风的应助被leotao采纳,获得10
2秒前
小溪苏完成签到 ,获得积分10
2秒前
3秒前
田様的应助被gaoyi12356采纳,获得10
3秒前
放鸿鸟于飞完成签到,获得积分10
3秒前
3秒前
Co完成签到,获得积分10
4秒前
4秒前
羽扇纶巾完成签到,获得积分10
4秒前
夏夏完成签到 ,获得积分10
4秒前
锦程完成签到,获得积分10
5秒前
5秒前
6秒前
七七酱发布了新的文献求助10
6秒前
liu45kf发布了新的文献求助10
6秒前
流苏完成签到,获得积分10
7秒前
慕青的应助被多多采纳,获得10
7秒前
乐空思的应助被羽扇纶巾采纳,获得30
8秒前
CEN发布了新的文献求助10
8秒前
Jasper的应助被mmyhn采纳,获得10
8秒前
9秒前
锦程发布了新的文献求助10
9秒前
七七完成签到,获得积分10
10秒前
小飞完成签到,获得积分10
10秒前
orixero的应助被sunying采纳,获得10
10秒前
lululu发布了新的文献求助20
11秒前
yuyi发布了新的文献求助10
11秒前
11秒前
11秒前
黄毛虎发布了新的文献求助10
11秒前
11秒前
龙凌音完成签到,获得积分10
11秒前
liukang172完成签到,获得积分10
11秒前
小马甲的应助被ying采纳,获得10
11秒前
大个的应助被吱吱采纳,获得10
12秒前
爱笑的大白菜完成签到 ,获得积分20
12秒前
DrSong完成签到,获得积分10
12秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187480
求助须知:如何正确求助?哪些是违规求助? 9575554
关于积分的说明 21841909
捐赠科研通 7785230
什么是DOI,文献DOI怎么找? 3434949
关于科研通互助平台的介绍 2559412
邀请新用户注册赠送积分活动 2481898